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remains unanswered. The aim of the study was to 
retrospectively review the changes in total testosterone in 
low risk prostate cancer patients treated with IMRT alone, in 
comparison with a RP cohort and to assess the correlation 
between dosimetric parameters for the testes and changes in 
the level of testosterone. 
 
Material and Methods: From 2009-2012 we studied 115 men 
in this cross-sectional study. 92 patients underwent RP and 
23 patients were treated with IMRT exclusively. The patients 
were treated with IMRT to the prostate and seminal vesicles 
for a total dose of 76 Gy (2 Gy/d, 5d/w) with 6 MV photons. 
We measured serum levels of total testosterone, at baseline 
and at 3, 12 and 24 months (m) after treatment. We 
calculated the mean and maximum dose in the testes and the 
distance between PTV-testes. T –test and Pearson correlation 
index (PI) were used for statistical purposes. 
 
Results: Patients undergoing RP were younger with IMRT 
(64.3 vs 72 years, p<0.0001). No differences regarding serum 
hormonal levels were found at baseline between the two 
groups. At 3months the testosterone levels were significantly 
lower in IMRT group (360,3 vs 414,83 ng/dl) in comparison 
with RP group (p <0,039). At 12 months testosterone levels 
remained significantly lower (339,89 vs 402,39 ng/dl, p 0,03) 
in the IMRT group. 
In the IMRT group the mean and maximum testes doses (± SD) 
were 0.472Gy (±0.195) and 0.896 Gy (±0.382) respectively. At 
3 months, the mean testosterone reduction was 29.4 ng/dl (± 
111.3), without correlation among the mean and maximum 
dose to the testes (p=0.2). At 12 months, 60% (12/20) of the 
patients had recovered their basal testosterone levels as well 
as 61% (11/18) at 24 months. The PI didn´t show any 
statistical significance related with testosterone kinetics and 
dosimetric parameters at 12 and 24 months. In the 
multivariate analyses, we didn´t find any significant 
relationship regarding: scattered doses in testes; total dose 
to the prostate; distance between PTV-testes or age, with 
testosterone recovery. 
 
Conclusion: Despite IMRT for localized prostate cancer 
leading to low doses to the testes, we observed a decline in 
total testosterone higher than RP. Nevertheless, it doesn´t 
seem to correlate with either dosimetric parameters or the 
scattered dose in testes. More studies are needed to 
elucidate the role that the prostate may play as an endocrine 
organ itself. 
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Purpose or Objective: To investigate the correlation 
between initial prostate volume and the probability of 
developing acute Obstructive Voiding Symptoms (OVS) during 
the course of moderate hypofractionated (HF) prostate RT. 
 
Material and Methods: Data from patients (n=181) 
undergoing IMRT delivered, daily Cone Beam CT guided, HF 
RT were retrospectively analyzed. Two treatment schedules 
were considered: HF1 (2.6 Gy/fr, 27 fr; n=107) and HF2 (3.15 
Gy/fr, 20 fr, 4 days a week; n=74). Patients verifying: 1. 
previous OVS score 3 or greater according the International 
Prostatic Symptoms Score (IPSS), 2. CTVs encompassing 
volume outside the prostatic capsule (i.e. margin for 
extracapsular extension or seminal vesicles invasion), 3. 
presence of central calcification masses or 4. altered RT 
schedules for reasons other than OVS, were excluded. 
Measured HF1 and HF2 median prostate volumes as contoured 
in the simulation CT image were 61.0 cc [18.6, 157.7] and 
53.6 cc [18.5, 114.8], respectively. OVS was assessed 
according the RTOG/CTC v3.0 scale. Development of OVS G2 
or greater during treatment was considered as binary end-
point. Volume-effect correlation was evaluated by logit 
analysis, assuming a log-normal distribution. 
 
Results: OVS G2 or greater was found in HF1 (n=11) and HF2 
(n=10) patients. A few patients HF1 (n=1) and HF2 (n=5) 
needed urethral catheterization. Some patients (n=12) had 
their course of treatment modified due to OVS: temporary 
interruption of treatment (n=6), modified fractionation (n=5), 
urinary catheterization at treatment delivery (n=1). Logit 
analysis showed that prostate volume did not correlate with 
OVS for HF1 patients (p > 0.05) but proved to be significantly 
predictive of OVS for HF2 patients (p = 0.0002). For this 
second arm, normalized gradient of the volume-effect 
regression curve was found to be γ50=7.8 [3.2-14.7] and 
ED50% = 95.7 cc [84.7-117.8] (see Figure). The Receiver 
Operating Characteristics analysis (ROC) showed excellent 
predictive capabilities of the model, with Area Under the 
Curve AUC=0.94. Based on these findings, a volume cutoff 
value of 80 cc, corresponding to an acceptable 20% risk of 
OVS G2 or greater was selected. 
 
 
 
Conclusion: Depending on the HF scheme, patients with 
larger prostate volume will face an increasing risk of OVS. 
This may compromise their quality of life and alter the RT 
treatment schedule. In this work, we successfully correlated 
OVS to prostate volume. This predictive model can be 
exploited for decision-making prior to treatment. In our 
Institution, patients with prostate volume larger than 80 cc 
will be preferably addressed to the HF1 schedule due to the 
risk of OVS. 
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Purpose or Objective: Comorbidity assessment is essential to 
triage of care for men with prostate cancer. Specially in 
these with an expectative of life less of ten years. We made 
a Spanish validation of comorbid revised Charlson index (RCI) 
applied to prostate cancer.  
 
Material and Methods: A group of 619 consecutive patients 
of Prostate Cancer diagnosed between 1994- 2007 were send 
for clinical assessment at Radiation Oncology Department of 
Hospital Clinic of Bacelona. 
A long the period of follow-up ( till November 2014) 69 
patients deceased for Prostate Cancer and were excluded in 
this study in order to determine the risks of mortality 
associated with comorbidities measured by the RCI. 
